VEGFA and oral cavity squamous cell carcinoma: In a prospective study, zoledronate reduced serum biomarkers of angiogenesis (vascular endothelial growth factor/VEGF) and bone turnover (C-terminal telopeptide/CTx) in cats with oral squamous cell carcinoma, suggesting effects on malignant osteolysis as well as indirect anti-cancer effects [21].